Welcome to our dedicated page for CATALENT news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on CATALENT stock.
Catalent, Inc. (symbol: CTLT) is a leading contract development and manufacturing organization (CDMO) that plays a crucial role in the global pharmaceutical and biotechnology industries. With over 80 years of experience, Catalent specializes in providing a comprehensive range of development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company operates under four main segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
At Catalent, innovation and expertise are at the core of their operations. The company is dedicated to accelerating the development and delivery of new treatments by leveraging its advanced technologies and extensive industry knowledge. Catalent's services span the entire lifecycle of a product, from initial drug development and clinical trials to commercial manufacturing and packaging. This end-to-end approach allows them to support pharmaceutical customers with long-term supply agreements and partnerships.
One of Catalent's key strengths lies in its global presence. The company operates over 50 state-of-the-art facilities across four continents, ensuring that it can meet the diverse needs of its clients worldwide. By providing tailored solutions and maintaining high standards of quality and reliability, Catalent has established itself as a trusted partner for many of the world's leading pharmaceutical companies.
Catalent's commitment to innovation is evident through its focus on drug delivery technologies. As a world leader in this field, the company has a proven track record of enhancing bioavailability, solubility, and permeability of drug compounds. These advancements not only improve the efficacy of treatments but also enhance patient compliance and outcomes. Catalent's expertise in developing more effective and convenient drug delivery methods has made a significant impact on the healthcare industry.
Financially, Catalent remains robust, with consistent revenue generation driven by its long-term contracts and diverse service offerings. The company's ability to adapt to market demands and invest in cutting-edge technologies has positioned it for sustained growth. Recent achievements include the expansion of their biologics capabilities and strategic collaborations with key industry players to advance cell and gene therapies.
In conclusion, Catalent, Inc. stands as a pivotal entity in the pharmaceutical and biotechnology sectors. Through their extensive range of services, global reach, and unwavering commitment to innovation, they continue to drive faster, more efficient development timelines and deliver superior manufacturing and packaging solutions. For investors and stakeholders, Catalent represents a vital player in the advancement of modern medicine and healthcare.
Catalent, Inc. (NYSE: CTLT) reported a robust third quarter for fiscal 2021, with net revenue of $1.05 billion, up 38% year-over-year. Net earnings were $231.8 million, including a $184 million gain from a business sale. Adjusted EBITDA grew 48% to $274.2 million, and the Biologics segment experienced a remarkable 117% revenue increase. The company has raised its fiscal 2021 guidance, expecting revenues between $3.875 billion to $3.975 billion.
Catalent, Inc. (NYSE: CTLT) will announce its financial results for Q3 of fiscal year 2021, ending March 31, 2021, before the market opens on May 4, 2021. The management will host a webcast at 8:15 a.m. ET to discuss the results. Investors can access the event via Catalent's website, where a supplemental slide presentation will also be available prior to the webcast. Catalent has over 85 years of experience, employs approximately 15,000 staff, and reported over $3 billion in revenue for fiscal 2020.
Moderna and Catalent have expanded their strategic collaboration to include a new high-speed vial filling line at Catalent's Bloomington, Indiana facility dedicated to manufacturing the Moderna COVID-19 Vaccine and other investigational programs. This partnership, initiated in 2016, has previously supported the production of 100 million vaccine doses. The new filling line aims to enhance capacity for ongoing clinical trials and pandemic response efforts. Catalent's acceleration of the project allows for significant production efficiency, freeing up existing lines for other client programs.
Moderna and Catalent have expanded their strategic collaboration, dedicating a new high-speed vial filling line at Catalent's Bloomington facility for the production of the Moderna COVID-19 Vaccine. This expansion follows a successful milestone of 100 million doses achieved in March 2021. The new line will support not only the COVID-19 vaccine but also other investigational programs in Moderna's pipeline until June 2023. Catalent's investment of $50 million will enhance manufacturing capabilities and expedite project timelines.
Cybin, a biotechnology company focused on psychedelic therapeutics, has announced a new partnership with Catalent, the leader in drug delivery technologies. The agreement allows Cybin to utilize Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology for its novel drug CYB003, aimed at treating resistant psychiatric disorders. This innovative delivery method promises improved pharmacokinetics by enabling pre-gastric absorption. The project begins in April 2021 with feasibility studies on various ODT formulations.
Catalent, Inc. (NYSE: CTLT), a global leader in drug delivery and manufacturing, announced its executive leadership will present virtually at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 11:20 a.m. ET. A live webcast of the presentation will be available at investor.catalent.com and can be replayed afterward.
Catalent has over 85 years of experience, employs over 14,000 staff, and generated over $3 billion in revenue in fiscal year 2020.
Catalent, Inc. (NYSE: CTLT) announced a private offering of $550 million in 3.125% senior unsecured notes due 2029, increasing from the previously announced size by $75 million. The proceeds will be utilized to redeem existing 4.875% senior notes due 2026, cover related expenses, and enhance cash reserves for general corporate purposes. The offering is exempt from registration requirements and is expected to close on February 22, 2021. The notes will not be guaranteed by Catalent or its parent companies.
Catalent (NYSE: CTLT) announced its subsidiary, Catalent Pharma Solutions, plans to offer $475 million in senior unsecured notes due 2029 in a private offering. The proceeds will be used to redeem its 4.875% senior notes due 2026, cover related fees, and support general corporate purposes, including capital expenditures. The offering is aimed at qualified institutional buyers and is exempt from registration under Securities Act regulations. Notably, there is no guarantee that the offering will be completed or that the redemption of the 2026 notes will occur.
Catalent, Inc. (NYSE: CTLT) announced its financial results for Q2 FY2021, reporting net revenue of $910.8 million, a 26% increase from the previous year. Net earnings were $88.4 million, with earnings per share rising to $0.46. The Biologics segment saw impressive growth, with revenue up 79% year-over-year. Catalent raised its fiscal 2021 guidance, projecting net revenue between $3.80 billion and $3.95 billion. Adjusted EBITDA is expected to range from $950 million to $1,000 million.
Catalent, Inc. (NYSE: CTLT) will release its financial results for Q2 fiscal 2021 on February 2, 2021, before market open. A webcast discussing these results will be hosted at 8:15 a.m. ET the same day. The company, a leader in advanced delivery technologies and manufacturing solutions for healthcare products, generated over $3 billion in revenue in fiscal 2020. The webcast and supplemental materials will be accessible via Catalent's website.
FAQ
What is the current stock price of CATALENT (CTLT)?
What is the market cap of CATALENT (CTLT)?
What is Catalent, Inc.'s core business?
How many facilities does Catalent operate?
What segments does Catalent operate under?
What is Catalent known for in drug delivery technologies?
Who are Catalent's primary customers?
What recent achievements has Catalent made?
How does Catalent support drug development?
What distinguishes Catalent in the pharmaceutical industry?
What is the significance of Catalent's global presence?
How does Catalent ensure the quality of their services?
